Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of British Columbia
This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\> 50 years
Male \& female
Alzheimer's disease
Depressive episode
Clareo Health | Escitalopram and Depression in Elderly Alzheimer's Patients
